Fig. 3From: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialProgression-free survival (PFS) and overall survival (OS) in the chronic phase (A) or accelerated phase (B)Back to article page